Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi limited - potassium phosphate monobasic ; sodium phosphate dibasic dihydrate ; potassium hydroxide - concentrate for soln for inf - 170. 133.5 14.0 g/20ml - combinations of electrolytes

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - potassium phosphate, monobasic (unii: 4j9fj0hl51) (phosphate ion - unii:nk08v8k8hr), potassium phosphate, dibasic (unii: ci71s98n1z) (phosphate ion - unii:nk08v8k8hr) - potassium phosphate, monobasic 224 mg in 1 ml - potassium phosphates injection, usp is indicated as a source of phosphate, for addition to large volume intravenous fluids to prevent or correct hypophosphatemia in patients with restricted or no oral intake. it is also useful as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte of nutrient solutions. potassium phosphates is contraindicated in diseases where high potassium, high phosphate or low calcium levels may be encountered.

United States - English - NLM (National Library of Medicine)

hospira, inc. - monobasic potassium phosphate (unii: 4j9fj0hl51) (potassium cation - unii:295o53k152, phosphate ion - unii:nk08v8k8hr), dibasic potassium phosphate (unii: ci71s98n1z) (phosphate ion - unii:nk08v8k8hr, potassium cation - unii:295o53k152) - potassium phosphate, monobasic 224 mg in 1 ml - potassium phosphates injection, usp, 3 mm p/ml is indicated as a source of phosphorus, for addition to large volume intravenous fluids, to prevent or correct hypophosphatemia in patients with restricted or no oral intake. it is also useful as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions. the concomitant amount of potassium (k+ 4.4 meq/ml) must be calculated into total electrolyte dose of such prepared solutions.     safety has not been established for parenteral nutrition in pediatric patients due to the risk of aluminum toxicity. (see warnings) potassium phosphate is contraindicated in diseases where high potassium, high phosphorus or low calcium levels may be encountered.

United States - English - NLM (National Library of Medicine)

hospira, inc. - potassium phosphate, monobasic (unii: 4j9fj0hl51) (potassium cation - unii:295o53k152, phosphate ion - unii:nk08v8k8hr) - potassium phosphate, monobasic 224 mg in 1 ml

United States - English - NLM (National Library of Medicine)

cmp pharma, inc. - potassium phosphate, monobasic (unii: 4j9fj0hl51) (phosphate ion - unii:nk08v8k8hr), potassium phosphate, dibasic (unii: ci71s98n1z) (phosphate ion - unii:nk08v8k8hr) - potassium phosphates injection is indicated as a source of phosphorus in intravenous fluids to correct hypophosphatemia in adults and pediatric patients 12 years of age and older when oral or enteral replacement is not possible, insufficient or contraindicated. potassium phosphates injection is indicated as a source of phosphorus for parenteral nutrition in adults weighing at least 45 kg and pediatric patients 12 years of age and older weighing at least 40 kg when oral or enteral nutrition is not possible, insufficient or contraindicated. limitations of use safety has not been established for parenteral nutrition in adults weighing less than 45 kg or pediatric patients less than 12 years of age or weighing less than 40 kg due to the risk of aluminum toxicity [see warnings and precautions (5.5), use in specific population (8.4) ]. potassium phosphates injection is contraindicated in patients with: - hyperkalemia [see warnings and precautions (5.3) ] - hyperphosphatemia [see warnings and precautions (5.4) ] -

United States - English - NLM (National Library of Medicine)

carilion materials management - potassium phosphate, monobasic (unii: 4j9fj0hl51) (phosphate ion - unii:nk08v8k8hr, potassium cation - unii:295o53k152) - potassium phosphate, monobasic 500 mg - this product is contraindicated in patients with infected phosphate stones; in patients with severely impaired renal function (less than 30% of normal) and in the presence of hyperphosphatemia and hyperkalemia.

United States - English - NLM (National Library of Medicine)

beach products, inc. - potassium phosphate, monobasic (unii: 4j9fj0hl51) (phosphate ion - unii:nk08v8k8hr, potassium cation - unii:295o53k152) - potassium phosphate, monobasic 500 mg - this product is contraindicated in patients with infected phosphate stones; in patients with severely impaired renal function (less than 30% of normal) and in the presence of hyperphosphatemia and hyperkalemia.

United States - English - NLM (National Library of Medicine)

beach products, inc. - potassium phosphate, monobasic (unii: 4j9fj0hl51) (phosphate ion - unii:nk08v8k8hr, potassium cation - unii:295o53k152), sodium phosphate, monobasic, anhydrous (unii: kh7i04hpuu) (phosphate ion - unii:nk08v8k8hr, sodium cation - unii:lyr4m0nh37) - potassium phosphate, monobasic 305 mg - this product is contraindicated in patients with infected phosphate stones, in patients with severely impaired renal function (less than 30% of normal) and in the presence of hyperphosphatemia.

United States - English - NLM (National Library of Medicine)

novel laboratories, inc. - sodium phosphate, monobasic, monohydrate (unii: 593yog76rn) (sodium cation - unii:lyr4m0nh37), sodium phosphate, dibasic anhydrous (unii: 22ado53m6f) (sodium cation - unii:lyr4m0nh37) - sodium phosphate, monobasic, monohydrate 1.105 g - monobasic sodium phosphate and dibasic sodium phosphate tablets are indicated for cleansing of the colon as a preparation for colonoscopy in adults 18 years of age or older. monobasic sodium phosphate and dibasic sodium phosphate tablets are contraindicated in patients with biopsy-proven acute phosphate nephropathy. monobasic sodium phosphate and dibasic sodium phosphate tablets are contraindicated in patients with a known allergy or hypersensitivity to sodium phosphate salts or any of its ingredients. laxatives and purgatives (including monobasic sodium phosphate and dibasic sodium phosphate tablets) have the potential for abuse by bulimia nervosa patients who frequently have binge eating and vomiting.

Canada - English - Health Canada

fresenius kabi canada ltd - potassium phosphate monobasic; potassium phosphate dibasic - solution - 224mg; 236mg - potassium phosphate monobasic 224mg; potassium phosphate dibasic 236mg - replacement preparations